{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:37:27Z","timestamp":1793090247545,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105624","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:16:20Z","timestamp":1790698580000},"page":"105624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Abundance is not survival: Intratumoural immune-cell fate as a missing endpoint in antibody-drug conjugate and checkpoint blockade combinations for triple-negative breast cancer"],"prefix":"10.1016","volume":"227","author":[{"given":"Zhenjia","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105624_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003536","article-title":"Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer","volume":"9","author":"Alessi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105624_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/2326-6066.CIR-24-0103","article-title":"Selective STING activation in intratumoral myeloid cells via CCR2-directed antibody-drug conjugate TAK-500","volume":"13","author":"Appleman","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib3","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1565859","article-title":"Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells","volume":"8","author":"Bauzon","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105624_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1507371","article-title":"Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features","volume":"15","author":"Boissi\u00e8re-Michot","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1535-7163.MCT-22-0440","article-title":"Payload-binding Fab fragments increase the therapeutic index of MMAE antibody-drug conjugates","volume":"22","author":"Bordeau","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105624_bib7","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-24-2449","article-title":"XMT-2056, a HER2-directed STING agonist antibody-drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells","volume":"31","author":"Bukhalid","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105624_bib9","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib10","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105624_bib11","doi-asserted-by":"crossref","first-page":"E566","DOI":"10.1073\/pnas.1424927112","article-title":"Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils","volume":"112","author":"Casbon","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105624_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101353","article-title":"Mechanisms of resistance to antibody-drug conjugates in breast cancer","volume":"85","author":"Cerci","year":"2026","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.critrevonc.2026.105624_bib13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-25-0682","article-title":"Immune reprogramming of tumor microenvironments by cytotoxic antibody-drug conjugate payloads","volume":"25","author":"Chakravorty","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105624_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105624_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-13810-w","article-title":"silico decrypting of the bystander effect in antibody-drug conjugates for breast cancer therapy","volume":"15","author":"Cruz","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105624_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1026293","article-title":"Mitochondrial topoisomerase 1 inhibition induces topological DNA damage and T cell dysfunction in patients with chronic viral infection","volume":"12","author":"Dang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","article-title":"TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer","volume":"33","author":"de Mingo Pulido","year":"2018","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105624_bib18","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.15698\/cst2025.08.311","article-title":"Datopotamab deruxtecan induces hallmarks of immunogenic cell death","volume":"9","author":"Forveille","year":"2025","journal-title":"Cell. Stress."},{"key":"10.1016\/j.critrevonc.2026.105624_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2514050","article-title":"Patritumab deruxtecan induces immunogenic cell death","volume":"14","author":"Forveille","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105624_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105624_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105624_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.06.012","article-title":"SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive\/HER2-negative breast cancer","author":"Garrido-Castro","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib24","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-23-2812","article-title":"Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer","volume":"84","author":"Gedik","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.critrevonc.2026.105624_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1011617","article-title":"A 31-plex panel for high-dimensional single-cell analysis of murine preclinical models of solid tumors by imaging mass cytometry","volume":"13","author":"Glasson","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.cell.2018.07.010","article-title":"Deep profiling of mouse splenic architecture with CODEX multiplexed imaging","volume":"174","author":"Goltsev","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105624_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2026.153205","article-title":"Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytes","volume":"231","author":"Gomis","year":"2026","journal-title":"Immunobiology"},{"key":"10.1016\/j.critrevonc.2026.105624_bib29","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-25-5849","article-title":"Antibody-drug conjugates synergize with agonist anti-CD137 monoclonal antibodies in solid tumors","author":"Gomis","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1083\/jcb.83.1.82","article-title":"Rapid stimulation of pinocytosis in human carcinoma cells A-431 by epidermal growth factor","volume":"83","author":"Haigler","year":"1979","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105624_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105624_bib33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105624_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115177","article-title":"G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer","volume":"5","author":"Hollm\u00e9n","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105624_bib35","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3389\/fimmu.2019.02534","article-title":"A 40-marker panel for high dimensional characterization of cancer immune microenvironments by imaging mass cytometry","volume":"10","author":"Ijsselsteijn","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib36","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2967\/jnumed.118.207753","article-title":"Dual-isotope cryoimaging quantitative autoradiography: investigating antibody-drug conjugate distribution and payload delivery through imaging","volume":"59","author":"Ilovich","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2026.105624_bib37","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105624_bib38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/1078-0432.CCR-25-0874","article-title":"DESTINY-Breast08: a phase Ib study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancer","volume":"32","author":"Jhaveri","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib39","article-title":"Beyond CD30: dual-targeting of malignant and regulatory T cells by brentuximab vedotin remodels the lymphoma microenvironment and overcomes resistance via BCL2 inhibition in mycosis fungoides","volume":"13","author":"Jiang","year":"2026","journal-title":"Adv. Sci. (Weinh. )."},{"key":"10.1016\/j.critrevonc.2026.105624_bib40","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105624_bib41","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.celrep.2019.08.057","article-title":"GEF-H1 signaling upon microtubule destabilization is required for dendritic cell activation and specific anti-tumor responses","volume":"28","author":"Kashyap","year":"2019","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105624_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2533488","article-title":"Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105624_bib43","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105624_bib44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","article-title":"Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates","volume":"21","author":"Khera","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105624_bib45","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2017.09.096","article-title":"Mass cytometric analysis reveals viable activated caspase-3+ luminal progenitors in the normal adult human mammary gland","volume":"21","author":"Knapp","year":"2017","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105624_bib46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105624_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1718838","article-title":"Recruitment of neutrophils by granulocyte colony-stimulating factor in cancer patients undergoing immunotherapy: the good, the bad, and the unknown","volume":"17","author":"Krykbaeva","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib48","article-title":"Interactions of antibody drug conjugate anti-tubulin and topoisomerase I inhibitor payloads with radiotherapy to potentiate immunotherapy","volume":"13","author":"Lesperance","year":"2026","journal-title":"Adv. Sci. (Weinh. )."},{"key":"10.1016\/j.critrevonc.2026.105624_bib49","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib50","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-17-0019","article-title":"Tumor-associated macrophages can contribute to antitumor activity through Fc\u03b3R-mediated processing of antibody-drug conjugates","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105624_bib51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-026-01799-2","article-title":"Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming","volume":"19","author":"Lu","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib52","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-022-01894-4","article-title":"Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS\/STING pathway","volume":"127","author":"Marinello","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105624_bib53","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00262-014-1565-4","article-title":"The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity","volume":"63","author":"Martin","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105624_bib54","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251316176","volume":"17","author":"McArthur","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/dmd.121.000503","article-title":"Simulating the selection of resistant cells with bystander killing and antibody coadministration in heterogeneous human epidermal growth factor receptor 2-positive tumors","volume":"50","author":"Menezes","year":"2022","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.critrevonc.2026.105624_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq0513","article-title":"Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models","volume":"11","author":"Metrangolo","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105624_bib57","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105624_bib58","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.3390\/molecules29235618","article-title":"Tumor-targeted cell-penetrating peptides reveal that monomethyl auristatin E temporally modulates the tumor immune microenvironment","volume":"29","author":"Mortaja","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2026.105624_bib59","doi-asserted-by":"crossref","first-page":"315ra188","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105624_bib60","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib61","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.87281","article-title":"CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment","volume":"12","author":"Muthana","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.critrevonc.2026.105624_bib62","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s10565-026-10183-2","article-title":"Mechanism of uptake and toxicity of a BCMA antibody drug conjugate with a MMAF payload by nonantigen expressing cells","volume":"42","author":"Newman","year":"2026","journal-title":"Cell. Biol. Toxicol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105624_bib64","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105624_bib65","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12964-024-01893-3","article-title":"Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells","volume":"22","author":"Oh","year":"2024","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.critrevonc.2026.105624_bib66","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105624_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2026.169841","article-title":"Molecular determinants of response and rational drug combinations for antibody-drug conjugates (ADCs) with topoisomerase I (TOP1) inhibitor payloads","volume":"438","author":"Pommier","year":"2026","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib68","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib69","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1080\/14796694.2026.2701483","article-title":"TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10","volume":"22","author":"Rugo","year":"2026","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.182.2.389","article-title":"Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products","volume":"182","author":"Sallusto","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105624_bib71","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105624_bib72","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s43018-026-01181-8","article-title":"First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b\/2 BEGONIA platform trial","volume":"7","author":"Schmid","year":"2026","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105624_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251327992","article-title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"17","author":"Schmid","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib74","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.annonc.2026.05.693","article-title":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib\/II BEGONIA study","volume":"37","author":"Schmid","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib75","article-title":"Understanding and overcoming antibody-drug conjugate resistance: biological mechanisms and emerging analytical frameworks in breast cancer","volume":"13","author":"Seo","year":"2026","journal-title":"Adv. Sci. (Weinh. )."},{"key":"10.1016\/j.critrevonc.2026.105624_bib76","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","article-title":"Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma","volume":"78","author":"Sili\u0146a","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib77","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1124\/jpet.119.262287","article-title":"Evolution of the systems pharmacokinetics-pharmacodynamics model for antibody-drug conjugates to characterize tumor heterogeneity and in vivo bystander effect","volume":"374","author":"Singh","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.critrevonc.2026.105624_bib78","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105624_bib79","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1158\/0008-5472.CAN-25-2998","article-title":"A MERTK-targeting antibody-drug conjugate selectively depletes M2 tumor-associated macrophages and MERTK-expressing cancer cells","volume":"86","author":"Takeda","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib80","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2220466","article-title":"A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells","volume":"15","author":"Tan","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.critrevonc.2026.105624_bib81","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105624_bib82","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1080\/14796694.2024.2357534","article-title":"OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (\u00b1 capecitabine) for residual triple-negative breast cancer","volume":"20","author":"Tolaney","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70219","article-title":"Innate immune cell infiltration induced by polatuzumab vedotin contributes to the antitumor effect in mouse models","volume":"7","author":"Tomita","year":"2026","journal-title":"EJHaem"},{"key":"10.1016\/j.critrevonc.2026.105624_bib84","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.3390\/cancers14133282","article-title":"Development of lymphopenia during therapy with immune checkpoint inhibitors is associated with poor outcome in metastatic cutaneous melanoma","volume":"14","author":"Tomsitz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105624_bib85","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105624_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007158","article-title":"Delayed vaccine-induced CD8+ T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication","volume":"11","author":"van der Sluis","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105624_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027690","article-title":"Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism","volume":"6","author":"Waight","year":"2011","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105624_bib88","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.14323","article-title":"Systemic glucocorticoid immunosuppression and survival among immune checkpoint inhibitor recipients","volume":"9","author":"Wan","year":"2026","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.critrevonc.2026.105624_bib89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41416-024-02917-y","article-title":"Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer","volume":"132","author":"Wang","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105624_bib90","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2023.08.058","article-title":"Severe lymphopenia during chemoradiation therapy for esophageal cancer: comprehensive analysis of randomized phase 2B trial of proton beam therapy versus intensity modulated radiation therapy","volume":"118","author":"Wang","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105624_bib91","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","article-title":"Spatiotemporal quantification of HER2-targeting antibody-drug conjugate bystander activity and enhancement of solid tumor penetration","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib92","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012265","article-title":"TROP2\/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer","volume":"14","author":"Wu","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105624_bib94","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41419-023-06073-8","article-title":"A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway","volume":"14","author":"Wu","year":"2023","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105624_bib95","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/cells15090803","article-title":"uPAR-targeting cytotoxic antibody-drug conjugates selectively deplete proinflammatory myeloid cells for autoimmune indications","volume":"15","author":"Xiang","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105624_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103012","article-title":"Combining antibody-drug conjugates with immune checkpoint inhibitors: a new paradigm for breast cancer therapy","volume":"140","author":"Xu","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105624_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2026.101004","article-title":"Mature tertiary lymphoid structures in breast cancers are associated with antitumor immunity and better prognosis","volume":"39","author":"Yu","year":"2026","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105624_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000860","article-title":"CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity","volume":"8","author":"Zammarchi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105624_bib99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21873\/anticanres.17391","article-title":"Eribulin induction of immunogenic cell death (ICD): comparison with other cytotoxic agents and temporal relationship of ICD biomarkers","volume":"45","author":"Zang","year":"2025","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.critrevonc.2026.105624_bib100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.172914","article-title":"A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders","volume":"8","author":"Zhang","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2026.105624_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114141","article-title":"Batf3+ DCs and the 4-1BB\/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1\/PD-L1 blockade efficacy","volume":"43","author":"Ziblat","year":"2024","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105624_bib102","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:52:59Z","timestamp":1793087579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":102,"alternative-id":["S1040842826005111"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105624","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abundance is not survival: Intratumoural immune-cell fate as a missing endpoint in antibody-drug conjugate and checkpoint blockade combinations for triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105624"}}